Skip to contentSkip to navigation

Anti-B2GP1 Antibodies, Anti-beta-2-glycoprotein Antibodies


Anti-beta-2-glycoproteins (anti-B2GP1 antibodies, anti-beta-2-glycoprotein antibodies) are antibodies produced by an individual’s immune system against his or her own phospholipids. These phospholipids are found on the surface of the platelets responsible for blood clotting (clot formation). Antibeta-2-glycoproteins (anti-B2GP1 antibodies, anti-beta-2-glycoprotein antibodies) are often responsible (with lupus anticoagulants and anticardiolipins) for abnormal clot formation in veins (phlebitis) and arteries (arterial thrombosis). They are involved in antiphospholipid syndrome, which manifests itself, among other things, by problems during pregnancy (repeated miscarriages in the second or third trimester, preeclampsia), headaches, strokes, chest pain, cognitive changes, epileptic seizures, memory loss, etc.

A negative result for anti-beta-2-glycoproteins (anti-B2GP1 antibodies, anti-beta-2-glycoprotein antibodies) does not eliminate the possibility of anti-phospholipid syndrome, especially if the right signs and symptoms and other antiphospholipid antibodies (circulating anticoagulants, anticardiolipins) are present. A persistent positive result (still positive 12 weeks later) is compatible with antiphospholipid syndrome. A low or moderate isolated positive result (not repeated) may be observed under other conditions, including acute infections. In an individual with another autoimmune disease such as systemic lupus erythematosus, the presence of anti-beta-2-glycoprotein antibodies (anti-B2GP1 antibodies) increases the risk of clot formation in veins and arteries.

Term of the Week

Predictive medicine

Medicine that links medical knowledge with data to predict a patient’s potential health problems. Examples include artificial intelligence and genetics.